Hims & Hers Health (NYSE:HIMS) Shares Down 1.5% - Should You Sell?

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) traded down 1.5% during trading on Wednesday . The stock traded as low as $52.90 and last traded at $53.91. 31,360,164 shares were traded during mid-day trading, an increase of 1% from the average session volume of 31,143,207 shares. The stock had previously closed at $54.73.

Analysts Set New Price Targets

Several brokerages have commented on HIMS. UBS Group reiterated a "mixed" rating on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Citigroup restated a "sell" rating and issued a $30.00 price target (up from $25.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Piper Sandler reaffirmed a "neutral" rating and set a $39.00 price target (up previously from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Finally, TD Cowen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating and cut their price target for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $38.00.

Hims & Hers Health Price Performance

The firm has a market capitalization of $12.63 billion, a P/E ratio of 128.28 and a beta of 2.09. The business's 50-day moving average is $41.72 and its 200 day moving average is $36.90.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.08. The firm had revenue of $586.01 million during the quarter, compared to analysts' expectations of $535.21 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company's quarterly revenue was up 110.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.05 EPS. Analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other news, COO Melissa Baird sold 67,687 shares of the company's stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $34.84, for a total value of $2,358,215.08. Following the completion of the transaction, the chief operating officer now owns 751,243 shares of the company's stock, valued at $26,173,306.12. This represents a 8.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 128,127 shares of Hims & Hers Health stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $33.98, for a total transaction of $4,353,755.46. Following the sale, the chief executive officer now owns 173,655 shares in the company, valued at approximately $5,900,796.90. This represents a 42.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 617,367 shares of company stock valued at $25,227,888. Company insiders own 13.71% of the company's stock.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds have recently modified their holdings of the business. Farallon Capital Management LLC grew its position in shares of Hims & Hers Health by 64,338.5% in the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after buying an additional 8,364,000 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in Hims & Hers Health by 192.0% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock valued at $152,436,000 after acquiring an additional 4,145,305 shares during the last quarter. Vanguard Group Inc. increased its position in Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock valued at $489,817,000 after purchasing an additional 2,020,722 shares during the period. Nuveen LLC bought a new position in Hims & Hers Health during the 1st quarter worth approximately $58,403,000. Finally, Yong Rong HK Asset Management Ltd bought a new position in Hims & Hers Health during the 4th quarter worth approximately $41,104,000. Institutional investors and hedge funds own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.